MK 3475/Pembrolizumab +MK5890/MK4830/Lenvatinib + Etoposide/Platinum
Categoría
Drugs Multinational Subsidiaries
Tipo de registro
Biotech Sanitaria
Nombre socio
Producto / Servicio
MK 3475/Pembrolizumab +MK5890/MK4830/Lenvatinib + Etoposide/Platinum
Tipo
Biodrugs/ Drugs
Area terapéutica
Oncología
Propiedades/Indicación
Platform trial: To Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination w/Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants w/Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)
Fase de desarrollo
P II